Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169752 · ClinicalTrials.gov registry record · NA
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
A NA study, sponsored by National Jewish Health.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT02169752 is a NA study that was terminated before completion, run by National Jewish Health. The registered enrollment target is 7 participants.
The verdict
NCT02169752, a NA study, was terminated before completion, sponsored by National Jewish Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension. It is also looking at using right ventricle function changes as a marker of disease severity.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-05-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169752
The ClinicalTrials.gov registry entry for NCT02169752 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT02169752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169752 about?
NCT02169752 is a clinical study titled "Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension". This research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension. It is also looking at using right ventricle function changes as a marker of disease severity.
What is the current status of trial NCT02169752?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2012-09. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02169752?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT02169752?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.